NASDAQ: STAA · Medical Instruments & Supplies

STAAR Surgical (STAA) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values STAAR Surgical (STAA) at $24.60 a share. The stock last closed at $26.01, which puts the model's fair value 5.4% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. STAAR Surgical Company.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$24.60midpoint of 2,000 simulations
Last close$26.01NASDAQ: STAA
Gap to fair value-5.4%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $23.51 to $24.60 (+4.6%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.

What the model makes of itThe price of $26.01 is 5.4% above it: Fairly valued, on a medium evidence grade.

What's nextNext report on 2 Mar 2027. Options prices imply a move of about 17% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give STAA?

The calibrated range for STAA over 63 trading days is $21.40 to $31.92. It sits around the last close, and its width comes from the volatility that STAA's own options imply (59% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $20.24 to $29.95. In 38% of the simulations the fair value came out above the price the model ran on.

$15.77$39.10
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $24.60. Dashed line: the last close, $26.01.

Faircurve Insights · 14 Nov 2026

STAAR Surgical Company, along with its subsidiaries, specialises in ophthalmological solutions. It designs, develops, manufactures and commercialises implantable lenses for vision correction, complete with the sophisticated delivery.

The model's fair value for STAAR Surgical is $24.60 a share, as of 14 Nov 2026. This is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $23.51, so the fair value moved +4.6%. In the model's own words, analysts raised their next-twelve-month EBITDA estimates: most of the move. The calibrated range over 63 trading days is $19.67 to $29.22. It is built from the fair value, since there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The business scores 62 out of 100 on the model's overall quality score, a composite of six factors measured against comparable companies. Three factors stand out. Balance sheet scores 100, with net debt to EBITDA at -5.87x against a peer median of 2.54x. Stability scores 0, with five-year EBITDA margin downside volatility at 15.1 pts against a peer median of 1.6 pts. Growth quality scores 55, with trailing revenue growth at -23.7% against a peer median of 9.7%. The model compares the company with LeMaitre Vascular, DENTSPLY SIRONA, ICU Medical, Merit Medical Systems, Teleflex and AptarGroup.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does STAA report earnings, and how has the stock reacted?

STAAR Surgical's next earnings report is scheduled for 2 Mar 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 13.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. STAA's 30 day implied volatility works out to about 17.1% over one month.

On 11 Nov 2026 STAA moved 11.8% in one session, against the 3.0% a day that options had priced: 3.9 times the implied size.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across STAA's last 8 reports, ignoring direction, was 4.8%.

0%10%20%30%13.8%4.3%30 Oct '24no quote27.1%11 Feb '2519.6%0.3%6 Aug '25no quote5.3%5 Nov '25no quote0.9%3 Mar '2613.6%13.6%13 May '2617.8%1.6%12 Aug '2613.5%6.2%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in STAA

10%15%20%25%30%35%4 Nov '26 report12 Aug '26 report13 May '26 report3 Mar '26 report17% at 16 Nov '2621 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 17% on 21 Nov 2025, reached 32% on 26 Dec 2025 and reads 17% on 16 Nov 2026. The marks are report dates.

How does STAA score on business quality?

STAAR Surgical's overall quality score is 62 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.505.2%ROIC3.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).8933.67xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.55-23.7%Revenue growth, trailing9.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.830.5%Net buybacks / market value0.1%
Balance sheetNet debt to EBITDA and interest coverage.100-5.87xNet debt / EBITDA2.54x
StabilityDownside volatility of the EBITDA margin over the last five years.015.1 ptsEBITDA margin downside volatility, 5y1.6 pts

How does STAA compare with similar companies?

The companies in medical instruments & supplies closest to STAAR Surgical in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
LMAT LeMaitre Vascular, Inc.$77.01$93.66+21.6%Undervalued
XRAY DENTSPLY SIRONA Inc.$8.95$13.35+49.2%Undervalued
NVST Envista Holdings Corp$24.03$25.54+6.3%Low evidence grade
ICUI ICU Medical, Inc.$181.87$202.62+11.4%Fairly valued
EMBC Embecta Corp.$6.25$7.68+22.9%Low evidence grade
MMSI Merit Medical Systems, Inc.$86.35$82.63-4.3%Fairly valued
TFX Teleflex Incorporated$157.10$169.00+7.6%Fairly valued
ATR AptarGroup, Inc.$143.17$137.10-4.2%Fairly valued

What the comparable companies' multiples alone would give for STAA, the peer-implied price, is $11.59 a share on this run. The fair value weighs that against the company's own multiple.

All medical instruments & supplies stocks ranked by gap to fair value

STAAR Surgical at a glance

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery.

Market value
$1.3B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Revenue expected, next twelve months
$366M
Consensus revenue growth, next fiscal year
+41.9%
Analysts with estimates
5
Beta to the US market
0.30
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. STAA was not among them.

How the fair value is worked out: the model prices STAAR Surgical on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for STAA was $23.51. As of 14 Nov 2026 it is $24.60, a change of +4.6%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about STAAR Surgical's valuation

Is STAAR Surgical stock undervalued or overvalued?

On Faircurve's model, STAA reads as Fairly valued as of 14 Nov 2026. The model's fair value is $24.60 a share against a last close of $26.01, a gap of -5.4%.

What is STAA's fair value?

$24.60 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $20.24 to $29.95.

What price range does the model give STAA?

$21.40 to $31.92 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does STAAR Surgical report earnings next?

The next report is scheduled for 2 Mar 2027. Companies can move their dates.

How much has STAA moved on past earnings reports?

Across its last 8 reports the median two session move was 4.8%, ignoring direction. The largest was -27.1% around the report of 11 Feb 2025.

How confident is the model in this valuation?

The model's evidence grade for STAA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on STAA

The model holds no idea open on STAA today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on STAA with their outcomes. A free account is enough.

Keep reading